((Sara M. Tinsley, Ph.D., ARNP, AOCN))
VYXEOS has demonstrated in animal models that it is delivered to the bone marrow, where it is taken up by leukemia cells to a greater extent than by normal cells and exerts an antileukemic effect.
The extended half-life of VYXEOS allows for greater drug exposure within the plasma and bone marrow.
At our institution, we assess bone marrow between Days 14 and 21, and we usually wait until Day 21 to allow the drug to work as long as possible.
Since we don’t want to extract bone marrow too often because it can be taxing on the patient, we may consider assessing the marrow based on the attending physician’s schedule—aligning it with the physician who has been closest to the patient's progress.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION